For the Inventor, By the Inventor

Enter assignee name

Theravectys

USPTO Granted Patents = 9

EPO Patents = 7

Trademarks = 1

Forward Citations = 20

Loading Chart...

Loading Chart...

17 inventors (with patents filed for the assignee):

Pierre Charneau (4 out of 35 patents)

Cecile Bauche (4 out of 7 patents)

Anne-Sophie Beignon (3 out of 4 patents)

4. Emeline Sarry (3 out of 5 patents)

5. Frederic Philippe Coutant (3 out of 5 patents)

6. Karine Courbeyrette (3 out of 3 patents)

7. Sebastian Amigorena (1 out of 11 patents)

8. Franck Perez (1 out of 9 patents)

9. Ana Bejanariu (1 out of 1 patent)

10. Sophie Agaugue (1 out of 1 patent)

11. Lorenzo Tibaldi (1 out of 1 patent)

12. Klervi Even-Desrumaux (1 out of 1 patent)

13. Dmitry Trubetskoy (1 out of 1 patent)

14. Cécile Bauche (1 out of 6 patents)

15. Mohamad Fakruddin Jamiluddin (1 out of 8 patents)

9 patents: Sort by Forward Citations

1. 10864265 - Lentiviral vectors for expression of hepatitis B virus (HBV) antigens (2020-12-15),

2. 10752668 - Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule (2020-08-25),

3. 9987351 - Lentiviral vectors for generating immune responses against human T Lymphotrophic Virus Type 1 (2018-06-05),

4. 9752160 - Use of non-subtype B gag proteins for lentiviral packaging (2017-09-05),

5. 9657311 - Lentiviral vectors containing an MHC class I, MHC class II, or B2 microglobulin upstream promoter sequence (2017-05-23),

6. 9328146 - Lentiviral gene transfer vectors and their medicinal applications (2016-05-03),

7. 8951535 - Lentiviral vectors containing an MHC class I promoter (2015-02-10),

8. 8709799 - Lentiviral gene transfer vectors and their medicinal applications (2014-04-29),

9. 8420104 - Lentiviral gene transfer vectors and their medicinal applications (2013-04-16),

Theravectys is a biotechnology company dedicated to the development of cutting-edge gene therapy solutions for the treatment of infectious diseases, cancers, and genetic disorders. Our innovative vector platform allows for the delivery of therapeutic genes directly into target cells, offering potential cures for a wide range of medical conditions. With a focus on research and development, Theravectys is committed to advancing the field of gene therapy to improve patient outcomes and quality of life.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 30 2025

9 Patents

#352 in Paris

#1,808 in France

Theravectys

Forward Citations = 20

17 inventors:

Pierre Charneau (4 out of 35 patents)

Cecile Bauche (4 out of 7 patents)

Anne-Sophie Beignon (3 out of 4 patents)

4. Emeline Sarry (3 out of 5 patents)

5. Frederic Philippe Coutant (3 out of 5 patents)

Please report any incorrect information to support@idiyas.com

Loading…